APPENDIX

Appendix 1. Screening guidelines for prostate cancer compared to guidelines from 2008

Organization	PSA/DRE	Current DRE and PSA	2008 DRE and PSA
		recommendations	recommendations ²³
Canadian Task Force on Preventive	PSA	PSA should be excluded from periodic health exam.	PSA should be excluded from periodic health exam.
Health Care ¹⁹	DRE	Insufficient evidence to include or exclude on periodic health exam.	Insufficient evidence to include or exclude on periodic health exam.
US Preventive Services Task Force ^{10,11}	PSA	Men aged 55–69 years should make an individual decision about whether to be screened after a conversation with their clinician. Men 70 years and older should not be screened.	Insufficient evidence to recommend for or against PSA testing for prostate cancer screening.
	DRE	Insufficient evidence to recommend for or against DRE for prostate cancer screening.	Insufficient evidence to recommend for or against DRE for prostate cancer screening
Canadian PSA Urological Association ⁵		For men electing to undergo PSA screening, start PSA testing at age 50 in most men and age 45 in men at increased risk of prostate cancer.	Men should be aware of potential benefits and risks to make an informed decision
	DRE	Average-risk men aged 50 years and older with 10-year life expectancy should be screened with both DRE and PSA	Men should be aware of potential benefits and risks to make an informed decision
American Urological Association ²⁰	PSA	For men ages 55–69 years, shared decision-making based on patients values and preferences. If patient	PSA testing should be offered to men over 50 with a life expectancy of more than 10 years

Spooner J, et al. The times they are a-changin': The evolution of prostate cancer screening practices and beliefs among primary care physicians in Victoria, British Columbia

		chooses screening, it should		
		be done every two years.		
	DRE	Insufficient evidence to	DRE screening should be	
		support the continued use of	offered to men over 50 with a	
		DRE as first-line screening	life expectancy of more than	
		test. May be useful with PSA	10 years.	
BC Cancer	PSA	Fit men aged 50–70 with at	Fit men age 50–70 with at	
Agency ^{12,13}		least 10 years life expectancy	least 10 years life expectancy	
		should be made aware of the	should be made aware of the	
		potential benefits and	potential benefits and risks. If	
		risks. If desired, PSA testing	desired, PSA testing should be	
		should be performed	performed annually for 2–3	
		annually for 2–3 years, and if	years, and if normal and stable,	
		normal and stable, then every	then every 2–3 years.	
		2–3 years.		
	DRE	DRE recommended during	Should be done annually in fit	
		routine physical checkup.	men 50-70 years or when	
			obstructive or other urinary	
			tract symptoms are present.	
European	PSA	Offer PSA testing in well-	Lack of evidence to support or	
Association of		informed men at elevated	disregard population-based	
Urology ²¹		risk of having prostate cancer	screening programs for	
		and >15-year life expectancy.	prostate cancer.	
	DRE	Offer DRE in well-informed	Lack of evidence to support or	
		men requesting an early	disregard population-based	
		diagnosis.	screening programs for	
			prostate cancer.	

DRE: digital rectal exam; PSA: prostate-specific antigen.

Appendix 2. Questionnaire delivered to primary care physicians in Victoria, BC. Initially used and by Hoag et al.¹⁴

Please enter your demographic information:

Gender: Male □	Female □	Years in Practic	e:	Age:	
Please check (✔) th	e box corresponding	to the answer that is	most appr	opriate.	
1a. Do you order Pro □ Always	state Specific Antiger Usually	* *	-		creening? Never
1b. If yes, at what ag	e do you begin screer	ning? $\Box \ge 40$ $\Box \ge 5$	50 □≥60	0 □≥70	□ other
\Box Always	ligital rectal exam (D □ <i>Usually</i> e do you begin screer	□ Sometimes	□ Rarely	,	<i>Never</i> □ other
3. Which of the follo	wing is your preferred $E \qquad \Box PSA \& DI$	d initial screening to		tate cancer?	
4. DRE is an importa supporting males over screening.				icient evider or prostate c	
□ Strongly agree		□ Strongl	y agree		
□ Agree		□ Agree			
□ Undecided		□ Undeci	ded		
□ Disagree		□ Disagre	ee		
☐ Strongly disagree		•	y disagree		
5. DRE training/teach supporting	hing is a valuable	10. Th	ere is insuf	fficient evide	ence
component of medica	al education.	D	RE as part	of prostate c	ancer
screening					
□ Strongly agree		□ Strongl			
□ Agree			Agree		
□ Undecided		□ Undecid	ded		
□ Disagree		□ Disagre	ee		

□ Strongly disagree	□ Strongly disagree	
6. PSA testing is a valuable tool for prostate	11. DRE is a valuable tool in prostate cancer	
cancer screening.	screening.	
□ Strongly agree	□ Strongly agree	
□ Agree	□ Agree	
□ Undecided	□ Undecided	
□ Disagree	□ Disagree	
□ Strongly disagree	☐ Strongly disagree	
7. The Medical Services Plan (MSP) should	12. I am comfortable with my knowledge on	
pay for PSA testing for prostate cancer testing. screening.	when MSP should be billed for PSA	
□ Strongly agree	□ Strongly agree	
□ Agree	□ Agree	
□ Undecided	□ Undecided	
□ Disagree	□ Disagree	
□ Strongly disagree	□ Strongly disagree	
8. I check the "MSP billable" box when ordering of	13. PSA testing leads to excess	
ordering PSA tests for prostate cancer screening	ng subsequent investigations (ie: biopsies).	
in asymptomatic men.	is subsequent investigations (ie. oropsies).	
□ Strongly agree	□ Strongly agree	
□ Agree	□ Agree	
□ Undecided	□ Undecided	
□ Disagree	□ Disagree	
□ Strongly disagree	□ Strongly disagree	
14. PSA testing and DRE should be utilized	15. If PSA is elevated on testing, it is	
in combination for prostate canc	eer screening. appropriate to refer for	
prostate biopsy.		
□ Strongly agree	□ Strongly agree	
□ Agree	□ Agree	
□ Undecided	□ Undecided	
□ Disagree	□ Disagree	
□ Strongly disagree	□ Strongly disagree	

16. Do pub	lished clinic	al guidelines/reco	mmendations influence your prostate cancer screening	
practices?	\Box Yes	$\square No$	\Box Undecided	
		~ ~	nes/recommendations on prostate cancer screening are	
=		= :	e choose ONE option only)	
□ American	n Urologica	l Association		
		and The Prostate C		
□ Canadian	n Task Force	e on Preventative I	Health Care	
□ Canadian	n Urological	Association		
□ Europear	n Associatio	n of Urology		
□ US Preve	entative Serv	vices Task Force		
□ Other (Pl	□ Other (Please specify)			
□ None/Pre	efer to decid	e own prostate car	ncer screening practices.	
18. Which	of the follow	wing factors would	l lead you to perform prostate cancer screening in an	
(otherwise)) asymptom	atic man (ie: orde	r PSA test and/or perform DRE)?	
Check () all that ap	ply.		
□ Suspicion	us findings o	on DRE	□ Patient requests PSA testing	
□ Family H	listory of pr	ostate cancer	□ Professional literature	
□ Lower un	rinary tract s	symptoms	☐ Media influence/promotion	
□ Hematur	ia		□ Poor quality diet	
□ Patient o	ver 50 years	of age	☐ Patient of African descent over 40 years old	
□ Previous	elevated PS	SA	□ Previous vasectomy	
□ Patient o	ver 40 years	of age	☐ History of infrequent ejaculation	
□ Professio	nal associat	ion guideline	□ Obesity/Sedentary lifestyle	
Recommen	dations			
□ Other (sp	ecify)			

The survey is now complete. Thank you for your time.